Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCO-101 + FOLFIRI in FOLFIRI‑resistant metastatic colorectal cancer
2024-518877-33-00Phase 2Completed
- Sponsor
- Scandion Oncology
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sco-101 in colorectal adenocarcinoma (mCRC) and metastatic colon cancer (mCRC) (3 arms), sponsored by Scandion Oncology. Primary endpoints: Safety and tolerability of SCO-101 + FOLFIRI, Maximum tolerated dose (MTD) of SCO-101 + FOLFIRI (Stages 1 and 3) and 1 more. Started Nov 2024; status: completed.
02
Drugs
sco-101
03
Conditions
colorectal adenocarcinoma (mCRC)metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on 2024-518877-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518877-33-00.